NCT07391163Completed
Protective Effect of N-acetylcysteine on Oxaliplatin-Induced Neuropathy in Colorectal Cancer
The Possible Protective Role of N-Acetylcysteine Against Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 10 Feb 2026
Brief summary (registry, in English)
This study investigates the possible protective role of N-Acetylcysteine against oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. The trial aims to evaluate whether N-Acetylcysteine can reduce the incidence and severity of neuropathy during chemotherapy.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 46 (actual)
- First submitted
- 13 Jan 2026
- Start date
- 1 Jan 2024
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- Tanta University
- Diseases
- Colorectal cancer
- NCT number
- NCT07391163
What you commit to
- Study type: Interventional
- Participants enrolled: 46
- From 1 Jan 2024 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior exposure to chemotherapy.
- Concomitant use of any drug has anti-oxidant activity or neuroprotective agent.
- Patients take any medication that increase acetyle choline either central or peripheral.
Other illness
- Patients with diabetes and other conditions that predispose to neuropathy.
- History of known allergy to oxaliplatin or other platinum agents.
- Patient was any cardiac disease.
Age
- Children \< 18 years old.
Other
- Pregnant and breastfeeding women.
Who the study is looking for
- Males and females aged ≥ 18 years old.
- Patients with histologically confirmed diagnosis of Stage III colorectal cancer and high risk Stage II.
- Patients who will be scheduled to receive modified FOLFOX-6.
- Patients with no contraindication to chemotherapy.
- Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5
- 109/L, platelet count ≥ 100 × 109/L and hemoglobin level ≥ 10 g/dl).
- Patients with adequate renal function (serum creatinine \< 1.5 mg/dl or creatinine clearance (ClCr) ˃ 45 mL/min).
- Patients with adequate liver function (serum bilirubin \< 1.5 mg/dl).
- Patients with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG) score.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta University - Faculty of Medicine ,oncology department, Tanta university hospital. Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
Related publications
- Protective effect of N-acetylcysteine on oxaliplatin-induced peripheral neuropathy in colorectal cancer: a randomized controlled trial.Cancer Chemother Pharmacol · 2026 · PMID 42909655
This page is information, not medical advice. Discuss any trial with your doctor.